 |
|
anti-CD20 monoclonal antibody AME-133v
An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody AME 133v specifically binds to CD20 antigen (B1), preventing mitogen-induced B-cell proliferation; inhibiting B-cell differentiation; and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells expressing CD20. The Fc portion of this monoclonal antibody has been engineered to possess a higher binding affinity for variant Fc receptors on T helper cells, resulting in an augmentation of the anti-tumor immune response. Because of Fc engineering, this agent may be significantly more potent than rituximab in inducing B cell-directed ADCC. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code names: | | AME-133v
LY 2469298 | | |
|
|
